Ironwood Pharmaceuticals Maintains FY 2025 Financial Guidance and Announces FY 2026 Financial Guidance
IRWDBOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today announced financial guidance for full year 2026. “Throughout 2025, we made significant progress in maximizing LINZESS while delivering sustained profits and cash flows in an effort to strengthen our financial position and maintain compliance with debt covenants over the coming
Ironwood Pharmaceuticals Reports Strong Third Quarter 2025 Results; Raises Full Year 2025 Financial Guidance
IRWDBOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today reported its third quarter 2025 results and recent business performance. “LINZESS delivered a strong third-quarter performance, driven by accelerated double-digit prescription demand growth combined with improved net pricing, which prompted us to raise our full-year 2025 financ
Ironwood Pharmaceuticals Reports Second Quarter 2025 Results; Maintains Full Year 2025 Financial Guidance
IRWDBOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today reported its second quarter 2025 results and recent business performance. “In the second quarter, LINZESS delivered $248 million in U.S. net sales with robust EUTRx demand growth of 10% year-over-year. Additionally, LINZESS net price was in-line with our expectations for the qu
Ironwood Pharmaceuticals Q1 Adj. EPS $(0.14) Misses $(0.05) Estimate, Sales $41.14M Miss $45.98M Estimate
IRWDIronwood Pharmaceuticals Raises 2025 Adj. EBITDA Guidance To Over $105M
IRWDWells Fargo Downgrades Ironwood Pharmaceuticals to Equal-Weight, Lowers Price Target to $1
IRWDJefferies Downgrades Ironwood Pharmaceuticals to Hold, Lowers Price Target to $0.7
IRWDLeerink Partners Maintains Market Perform on Ironwood Pharmaceuticals, Lowers Price Target to $1
IRWDIronwood Says Feedback From FDA Indicates That Confirmatory Phase 3 Trial Is Needed To Seek Approval Of Apraglutide For Patients With SBS With Intestinal Failure
IRWDIronwood Pharmaceuticals Receives Letter Of Nasdaq Non-Compliance Notification Regarding Late 2024 Form 10-K Filing
IRWDIronwood Pharmaceuticals 2025 Outlook: Expects Revenue Of $260M–$290M Vs. $287.583M Est., Sees Adjusted EBITDA Above $85M
IRWDIronwood Pharmaceuticals Q4 2024 Adj EPS $0.02 Misses $0.08 Estimate, Sales $90.55M Miss $93.82M Estimate
IRWDEarnings Preview: Ironwood Pharmaceuticals
IRWDIronwood Pharmaceuticals Will Present Late-breaking Data During The 2024 Digestive Disease Week Meeting From Its Phase 3 STARS Trial Of Apraglutide For Short Bowel Syndrome With Intestinal Failure
IRWDIronwood Pharmaceuticals Q1 2022 Earnings Conference Call On May 5, 2022 At 08:30 AM ET
IRWDIronwood Pharmaceuticals (NASDAQ:IRWD) will host a conference call at 08:30 AM ET on May 5, 2022, to discuss Q1 2022 earnings results.
